Anna KaltenboeckFormer Senior Health Advisor at Senate Committee on Finance, Chairman Ron Wyden (D-Ore.)
Anna is a health economist whose work focuses on how federal and commercial reimbursement policies shape the market for prescription drugs and new health technologies.
Anna previously led on drug pricing issues for the Senate Committee on Finance, including Medicare negotiation and Part D redesign provisions of the Inflation Reduction Act of 2022. In her prior role as Program Director for the Center for Health Policy and Outcomes and the Drug Pricing Lab at Memorial Sloan Kettering Cancer Center, she conducted research on the barriers and enablers of value-based pricing and measuring formulary adequacy of prescription drug plans. She also co-authored a report with ICER evaluating the performance of the FDA’s accelerated approval pathway.
Anna provides federal and state level technical assistance that is informed by her research and her previous experience as a consultant specializing in pricing and market access for pharmaceutical products. Examples of her work include advising Louisiana and Washington states’ on providing Hepatitis C treatment through subscription-based contracts, and CMS on Medicare payments to 340B entities, indication-specific pricing, and Part D redesign options.
Ms. Kaltenboeck received her undergraduate and master’s degrees in economics from Tufts University, and her MBA from Yale University.